Audit: QRS - Roseburia inulinivorans for Health & Longevity

Audit conducted on 07/09/2026 08:29 using AI4L / Opus 5

Iterations

Summary

Items	Count
Total	93
Passed	85
Failed	0
N/A	8
Pass Rate	100.00%

• Total = Passed + Failed + N/A
• Pass Rate = Passed / (Passed + Failed) × 100
• N/A items are excluded from the pass rate calculation

---

1. General Rules

#	Description	Result	Comments
1.1	Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER.	🟢	All protocol doses (5–10 g/day inulin, 10–20 g/day resistant starch, 2–5 g/day 2’-fucosyllactose), all nine biomarker targets, all benefit/risk headings and all gate items trace to ER lines 314–317, 296–310, 343–347, 403 and 437–453.
1.2	Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing.	🟢	“never been given to a person under study”, “never demonstrated in people”, “Mechanistically motivated and clinically untested”, “No established target” all carried through verbatim.
1.3	The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”).	🟢	Contraindications remain contraindications and interactions remain interactions; “it works unreliably” preserves the ER’s “the route to it is unreliable”.
1.4	The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc.	🟢	Both gates draw exclusively from ER Key Interactions & Contraindications; no Benefit- or Risk-Modifying Factor appears anywhere in the QRS.
1.5	PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact.	🟢	The QRS carries no PMIDs, citations, author names, NCT identifiers or brand names at all.
1.6	The QRS does not introduce new attributions.	🟢	No attributions of any kind are present.

2. Focus, Tone & Audience

#	Description	Result	Comments
2.1	The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing.	🟢	Matches the ER’s restrained, sceptical register (“the target is plausible, the route to it is unreliable”).
2.2	The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging	🟢	Quantified targets and doses paired with plain-language framing.
2.3	The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor	🟢	Protocol cells state substrates and amounts as observed practice, not as orders.
2.4	The QRS avoids language that implies medical or clinical advice	🟢	No prescriptive verbs; the footer disclaimer is the template’s fixed text.
2.5	The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising”	🟢	No instance of “recommended”, “should”, “advised” in the QRS’s own voice.
2.6	The QRS never addresses “the reader” directly — it presents evidence, not guidance	🟢	No second-person pronouns anywhere in the document body.
2.7	The QRS is written in plain language, avoiding unnecessary medical jargon	🟢	Technical terms that remain (calprotectin, hs-CRP, metagenome) are the ER’s own biomarker names and are unavoidable in the Monitoring table.
2.8	Information is presented in a concise and very compact manner	🟢	Every gate item, benefit and risk is a bare noun phrase; all ER rationale, mitigation and magnitude text is stripped.
2.9	It DOES NOT address the reader directly	🟢	Confirmed — no direct address.
2.10	The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review.	🟢	Functional-range targets (hs-CRP below 0.5 mg/L, HbA1c 4.8–5.3%) rather than conventional cut-offs.
2.11	The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort.	🟢	Assumes titrated substrate loading, three-day food records and shotgun stool sequencing.
2.12	The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort.	🟢	No simplified “just eat more fibre” framing.
2.13	Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience.	🟢	At-A-Glance states plainly that the lever is unreliable and the cost is symptomatic, which is the honest signal for a self-experimenting audience.
2.14	The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim.	🟢	The string “anti-aging” does not occur; the title uses “Health & Longevity”.
2.15	The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “injection” not “shot”; “adverse event” not “bad reaction”). Direct quotes from sources are exempt.	🟢	Body sections use clinical register throughout; the plain-language wording in At-A-Glance (“blood fats”, “gas and bloating”) is mandated by item 7.4.

3. Template Integrity

#	Description	Result	Comments
3.1	The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why”	🟢	All headings match the template byte-for-byte (lines 445, 491, 537, 559, 575, 605, 632, 636–638, 786). The absent “High” benefit and “Medium” risk labels are the display:none suppression required by items 12.5 and 13.5.
3.2	All “…” from the [qrs_template] are present in the the QRS.	🟢	All template variables present; the generic marker_#* and qualitative_item# rows are expanded to marker_1–9 and qualitative_item_1–5.
3.3	Spans that are not addressed in a checklist item are left unchanged	🟢	website="evidence_review", website="audit" and website="full_review" spans are intact at lines 423, 426, 439; the CSS block is byte-identical to the template.

4. Formatting

#	Description	Result	Comments
4.1	When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied”	N/A	No source ER section is empty; the two unpopulated tiers (Benefits High, Risks Medium) carry explanatory ER prose and are governed by items 12.5 and 13.5.
4.2	Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label.	🟢	“Primary substrate, chicory inulin”, “Second substrate, resistant starch”, “Third substrate, host-mimicking fucose sources” and “Persistence rather than half-life” are the ER’s bold labels verbatim (ER lines 343–347, 357).
4.3	Labels are not paraphrased, abbreviated, or invented.	🟢	The two remaining time labels use ER wording — “functional change” (ER line 403) and “abundance shift” (ER lines 357, 403). Marker names are verbatim from the ER biomarker table.
4.4	The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels.	🟢	No emoji code points occur in the file; the ER’s ⚠️ Conflicted markers were correctly dropped.
4.5	The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page.	🟢	Every section has been condensed to the floor permitted by the other mandatory items — gate items carry no severity/consequence/mitigation text, benefits and risks are bare headings, biomarker glosses and the ER’s Context/Notes column are dropped entirely, and no un-condensed ER prose remains anywhere.

---

5. Metadata

#	Description	Result	Comments
5.1	The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content.	🟢	Single comment spanning lines 2–14, immediately after <!doctype html> at line 1.
5.2	Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML.	🟢	Opening --- at line 3, closing --- at line 13; the preceding label text sits on line 2.
5.3	The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet.	🟢	Enclosed in an HTML comment and not duplicated in the header, footer or any span.
5.4	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Only duration: "00:03" is quoted, correctly, because the value contains a colon.
5.5	The filename of the source ER is stated as “er_filename: [er_filename]”	🟢	Line 4: er_filename: roseburia_inulinivorans_2026-0907-0556_Opus_ER.md.
5.6	Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]”	🟢	Line 5: qrs_prompt_version: 26.7.02, matching the QRS.md version badge.
5.7	Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430)	🟢	Line 6: qrs_creation_date: 2026-0907-0822.
5.8	The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]”	🟢	Line 7: qrs_creator_ai_nickname: Opus.
5.9	The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT)	🟢	“Opus” — single word, no version.
5.10	The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]”	🟢	Line 8: qrs_creator_ai_fullname: Opus 5.
5.11	The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4)	🟢	“Opus 5” — nickname plus version only.
5.12	The filename of the document is stated as “qrs_filename: [filename of this document]”	🟢	Line 9 matches the file’s actual name on disk.
5.13	All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting.	🟢	Re-verified across all nine keys; no stray whitespace or unnecessary quoting.

6. Page Title & Header

#	Description	Result	Comments
6.1	[page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &)	🟢	Line 22: “Roseburia inulinivorans for Health & Longevity - Quick Reference Sheet”.
6.2	[header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &)	🟢	Line 417 matches ER frontmatter canonical_topic with & encoded.
6.3	[header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY]	🟢	2026-0907-0822 → “09/07/2026” at line 421.
6.4	[header_subline_model] is set to [qrs_creator_ai_fullname]	🟢	Line 425: “Opus 5”.
6.5	No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker.	🟢	Header carries only title and the template’s fixed subline; the ER’s “Also known as” line is not reproduced.

7. At-A-Glance Section

#	Description	Result	Comments
7.1	[at_a_glance] is dense, execution-oriented summary of the ER Conclusion section	🟢	Compresses all three Conclusion paragraphs (ER lines 477–481) into what the target is, what it tracks with, and what acting on it costs.
7.2	[at_a_glance] is no longer than 60 words	🟢	58 words.
7.3	Every fact in [at_a_glance] is supported by a distinct passage in the ER.	🟢	“cannot be bought”/”never been given to a person under study” → ER 477; grip, bowel and nerve disease, plaque → ER 479; “worse blood fats in men” → ER 479; “diet is the only lever”/”unreliable”/”gas and bloating” → ER 481.
7.4	It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead	🟢	Uses “fibre-eating colon bacterium”, “blood fats”, “artery plaque”, “nerve disease” in place of species, lipid, atherosclerosis and demyelinating terminology; no acronyms.
7.5	It DOES NOT cite specific trials (names, years, sample sizes, p-values)	🟢	Refers only to “one study” with no name, year or sample size.
7.6	It DOES NOT cite effect sizes, relative risks, or statistical results	🟢	No numbers of any kind appear.

8. Contraindications

#	Description	Result	Comments
8.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All four items map to the “Populations who should avoid Roseburia inulinivorans” list at ER lines 314–317.
8.2	[stop_items] represent the Contraindications from the ER	🟢	Complete four-for-four correspondence with no additions.
8.3	Individual [stop_items] are formatted as <li></li>	🟢	Four <li> elements at lines 562–570.
8.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	The ER’s justifying clauses are stripped (e.g. “given documented bloodstream infection with live organisms from other genera”, “in whom a fermentable substrate load risks obstruction and distension”); the ER em-dash at line 314 carried threshold data, so it was correctly recast as a parenthetical rather than deleted.
8.5	Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	Neutrophil threshold 0.5 × 10⁹/L, the 90-day transplant window and “until the flare is controlled” are all retained; only the lay glosses (“a white blood cell measure”, “a transplant complication”, “a narrowed segment”) were trimmed.
8.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
8.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision.	🟢	The ER names four such populations and the section is correctly populated.
8.8	If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

9. Key Interactions

#	Description	Result	Comments
9.1	The section is derived from the ER Key Interactions & Contraindications section	🟢	All eight items map one-to-one onto the eight interaction bullets at ER lines 296–310.
9.2	[caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications	🟢	Eight of eight carried; no overlap with the four contraindication items.
9.3	Individual [caution_items] are formatted as <li></li>	🟢	Eight <li> elements at lines 578–595.
9.4	Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact.	🟢	Every “Severity — … Consequence: … Mitigation: …” clause is stripped, including the ER’s citation-bearing rationale for Bifidobacterium probiotics at line 306.
9.5	Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely).	🟢	All named-agent lists preserved (antibiotics, PPIs, laxatives, fibres, sweeteners, emulsifiers); only the “stomach-acid blockers:” gloss was trimmed.
9.6	When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol.	N/A	The ER uses no ranking notation inside parentheses in this section.
9.7	The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used.	🟢	The ER names eight interactions and the section is correctly populated.
9.8	If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g.	N/A	The section is not empty.

10. Protocol

#	Description	Result	Comments
10.1	The section is derived from the ER Protocol section	🟢	All three cells derive from ER Therapeutic Protocol lines 341–347.
10.2	The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section	🟢	The three named substrate routes are the ER’s only dosed, actionable protocols; the remaining bullets are competing approaches, timing and modifiers. The “no direct product exists” framing is folded into action_1_sub.
10.3	If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct actionable aspects; all three sets are used.
10.4	All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section.	🟢	Nine of nine populated; doses 5–10 g/day, 10–20 g/day and 2–5 g/day match ER lines 343, 345 and 347 exactly.

11. Time to Effect

#	Description	Result	Comments
11.1	The three sets of [time] items cover the three most important time-to-effect aspects from the ER	🟢	Downstream functional change (months), abundance shift (~10 days) and persistence/reversal (days to weeks) are the ER’s only three kinetic statements (lines 357, 403).
11.2	The sets are picked and ordered by the magnitude of the related benefit	🟢	Functional change leads because it maps to the Medium-tier strength benefit, the largest in the ER; abundance shift and reversal kinetics follow as supporting measures.
11.3	If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing.	N/A	The ER supplies three distinct aspects; all three sets are used.
11.4	All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER.	🟢	Nine of nine populated; “Months”, “About 10 days” and “Days to weeks” match ER lines 403 and 357.
11.5	If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel	N/A	The ER does provide time-to-effect information, so the section is correctly retained.

12. Benefits

#	Description	Result	Comments
12.1	The section is derived from the ER Expected Benefits section	🟢	Every listed item is an Expected Benefits sub-heading from ER lines 162–208.
12.2	Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative]	🟢	All four spans present at lines 539–552.
12.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare heading text only; the 29% grip-strength figure, cohort descriptions and all Magnitude paragraphs are omitted.
12.4	Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any benefit item.
12.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Line 539: <span data-qrs-var="benefits_high" style="display: none"></span>, correctly reflecting “No benefit reaches High” at ER line 158.

13. Risks

#	Description	Result	Comments
13.1	The section is derived from the ER Potential Risks & Side Effects section	🟢	Every listed item is a Potential Risks & Side Effects sub-heading from ER lines 234–274.
13.2	Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative]	🟢	All four spans present at lines 607–626.
13.3	Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact.	🟢	Bare heading text only; the 0–12 intolerance scale, AUC 0.684 and all trial descriptions are omitted.
13.4	Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved.	🟢	No parentheses remain in any risk item; the ER’s ⚠️ Conflicted marker is dropped.
13.5	If no items of a specific sub-section (high, medium, low, speculative) are present the respective is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing.	🟢	Line 613: <span data-qrs-var="risks_medium" style="display: none"></span>, correctly reflecting “No risk reaches Medium” at ER line 242.

14. Monitoring

#	Description	Result	Comments
14.1	The section is derived from the ER Monitoring section	🟢	Sourced from Monitoring Protocol & Defining Success, ER lines 433–445.
14.2	All measurable/quantifiable biomarkers from the Monitoring section are listed	🟢	All nine ER table rows are present in the same order, with targets reproduced exactly (butyrate 15–20%, calprotectin below 50 µg/g, hs-CRP below 0.5 mg/L, HbA1c 4.8–5.3%, triglycerides below 80 mg/dL, grip 40/25 kg, fibre 30–40 g/day, faecal pH 6.0–6.5).
14.3	[monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty.	🟢	Line 776 reproduces the ER’s baseline → weekly during titration → 3-month → 6-month → 6–12-month schedule from ER line 433.

15. Qualitative Assessment

#	Description	Result	Comments
15.1	The section is derived from the ER Monitoring section	🟢	Sourced from the “Qualitative markers worth tracking alongside the numbers” list at ER lines 449–453.
15.2	All subjective/qualitative biomarkers from the Monitoring section are listed	🟢	All five carried in order; only the Bristol scale gloss was trimmed.

Issues 07/09/2026 08:29

Pass rate 100.00%. No issues found.